Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Safety Study of COVID-19 Vaccine (TNX-1800) in Humans

Next Previous
Trial Profile

A Phase 1 Safety Study of COVID-19 Vaccine (TNX-1800) in Humans

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TNX 1800 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

    • Most Recent Events

    • 02 Nov 2023 According to a Tonix Pharmaceuticals Inc media release, NIAID will cover the full cost of the clinical trial, including operations and related analysis.Tonix will be responsible for providing clinical trial materials, and upon completion will have the right to rely on the findings in regulatory filings with the U.S. Food and Drug Administration (FDA) to support the approval of its COVID-19 vaccine and other vaccines based on the RPV platform.
    • 02 Nov 2023 According to a Tonix Pharmaceuticals Inc media release, the company announced that the National Institute of Allergy and Infectious Diseases (NIAID), will conduct a Phase 1 clinical trial with TNX-1800, NIAID will study TNX-1800 by percutaneous administration.
    • 02 Nov 2023 According to a Tonix Pharmaceuticals Inc media release, Phase 1 clinical trial of TNX-1800 expected to start in the second half of 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top